Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články
PubMed
29378728
DOI
10.1136/bjophthalmol-2017-311574
PII: bjophthalmol-2017-311574
Knihovny.cz E-zdroje
- Klíčová slova
- neoplasia, treatment medical,
- MeSH
- časové faktory MeSH
- injekce intravitreální MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru patofyziologie MeSH
- methotrexát aplikace a dávkování MeSH
- míra přežití MeSH
- nádory oka farmakoterapie mortalita patofyziologie MeSH
- nádory sítnice farmakoterapie mortalita patofyziologie MeSH
- nitrooční lymfom farmakoterapie mortalita patofyziologie MeSH
- přežití po terapii bez příznaků nemoci MeSH
- prognóza MeSH
- prokarbazin aplikace a dávkování MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- průtoková cytometrie MeSH
- retrospektivní studie MeSH
- rituximab aplikace a dávkování MeSH
- senioři MeSH
- sklivec účinky léků patologie MeSH
- vinkristin aplikace a dávkování MeSH
- zraková ostrost fyziologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- methotrexát MeSH
- prokarbazin MeSH
- rituximab MeSH
- vinkristin MeSH
BACKGROUND: Vitreoretinal lymphomas belong to the family of central nervous system (CNS) lymphomas. The optimal approach for the treatment of isolated primary vitreoretinal lymphoma is unclear because of the lack of large comparative clinical series. Combination of intravitreal and systemic chemotherapy is recommended in many reports. The aim of our retrospective study was to compare the survival rate and prognosis of patients with vitreoretinal lymphoma with and without CNS involvement. METHODS: Twenty patients with vitreoretinal lymphomas were observed between the years 2004and2016, 10 patients with primary vitreoretinal lymphoma and 10 with primary CNS lymphoma. To compare survival rates, we included 53 patients diagnosed with primary CNS lymphoma without vitreoretinal involvement between the years 2002and2011 from our haemato-oncology department. RESULTS: The 5-year survival rate was estimated 71% in patients with vitreoretinal lymphoma in our observation. Significantly longer 5-year overall survival (P˂0.01) was observed in patients with vitreoretinal lymphoma compared with patients with primary CNS lymphoma without vitreoretinal involvement. Progression-free survival was almost equal in both groups of patients with primary vitreoretinal lymphoma and primary CNS lymphoma (P=0.363). The relapse of lymphoma was frequent (50%-60%) with the median time to first relapse of 31 months. Combined treatment (local and systemic) in patients without CNS involvement significantly prolonged progression-free survival in our study (P˂0.05). CONCLUSION: Combined treatment of primary vitreoretinal lymphoma significantly delays the relapse of lymphoma compared with local therapy alone. Intraocular involvement brings significant positive prognostic value when overall survival is compared.
Citace poskytuje Crossref.org
